for symptomatic congenital cytomegalovirus disease.
The major challenge with linking CMV testing with newborn hearing screening is whether treatment with valganciclovir
would be of value in congenital CMV infection and isolated hearing loss.
, the oral prodrug of ganciclovir, has been well established to be as effective as IV ganciclovir for induction and maintenance therapy of CMV retinitis in HIV adult patients .
Due to immunosuppression, CMV infection was treated with valganciclovir
for about 4 weeks till viral load became undetectable.
The patient was started on valganciclovir
900 mg daily, prednisone dose was decreased to 5 mg daily and later discontinued, and rituximab was started.
45 mg/kg/day was continued for 4 months after ganciclovir treatment.
Nowadays, Ganciclovir and Valganciclovir
are first-line antiviral drugs to prevent or treat CMV infection .
He has also served as counsel for numerous generic pharmaceutical manufacturers, and has been instrumental in developing and implementing strategies for achieving early market entry of numerous generic products including atorvastatin (Lipitor) an valganciclovir
Owing to its cost-effectiveness, intravitreal ganciclovir injection is the current standard treatment in the SA public sector for active CMV retinitis infection,  even though systemic ganciclovir or valganciclovir
therapy is standard of care in other countries as these drugs assist in the prevention of systemic dissemination and improving survival.
It also took a hit from competition in the US for key products such as Valganciclovir
, Decitabine and Azacitidine.
Rintatolimod and valganciclovir
have showed some evidence of benefit, and graded exercise therapy has shown success.